Search

Top Biotech News (2 Jan 2025)

Pfizer Ends Hemophilia Gene Therapy Partnership with Sangamo Therapeutics

Summary:

Pfizer terminates collaboration on hemophilia A gene therapy, impacting Sangamo’s stock.

Pfizer has ended its partnership with Sangamo Therapeutics on the hemophilia A gene therapy, giroctocogene fitelparvovec, leading to a 56% drop in Sangamo’s stock. Pfizer will return rights to Sangamo by April 2025.

GSK Enters $300 Million Deal with Relation Therapeutics

Summary:

GSK partners with Relation Therapeutics to develop treatments for osteoarthritis and fibrotic diseases.

GSK has entered a $300 million partnership with London-based Relation Therapeutics to develop new treatments for osteoarthritis and fibrotic diseases, leveraging machine learning for drug discovery.

Autolus Receives FDA Approval for New CAR-T Cell Therapy

Summary:

Autolus gains FDA approval for Aucatzyl, a CAR-T cell therapy for leukemia.

Autolus, a UK biotech company, has received FDA approval for Aucatzyl, a new CAR-T cell therapy for acute lymphoblastic leukemia, aiming to reduce side effects associated with existing treatments.

Organoids Market Poised to Reach $12.8 Billion by 2030

Summary:

The organoids market is set to grow rapidly due to advancements in biotechnology and increased demand for personalized medicine.

A report predicts the global organoids market will reach $12.8 billion by 2030, driven by innovations in drug discovery, regenerative medicine, and personalized healthcare. The market shows exponential growth potential

Biopharma Must Demonstrate Data to Attract VC Dollars in 2025

Summary:

Biopharma companies are urged to focus on robust data to secure venture capital investments in 2025.

A PitchBook report highlights that venture capitalists prioritize biopharma companies with strong data in areas like clinical trials and patient outcomes, making data a critical factor for funding success.

Connect with Us

By submitting your details, you confirm that you have reviewed and agree with the Lambda Biologics Privacy Policy.